PRINCETON, N.J., April 17, 2012 /PRNewswire/ -- Argyle Therapeutics, Inc., ("Argyle"), a biopharmaceutical company focused on the discovery and development of innovative products in the field of dermatology has entered into a partnership with Brickell Biotech ("BBI") to develop a topical treatment for rosacea. The out-licensing deal is for a novel anti-inflammatory compound, SIG990, which has the potential to reduce erythema and decrease the pastules and pustules associated with the disease. The agreement provides Argyle milestone payments and royalties with Brickell receiving the exclusive rights for SIG990 in the field of dermatology.
Several topical rosacea treatments are currently on the market or in development. However, these drugs either have safety concerns or only treat the erythema or inflammatory lesions associated with rosacea, but not both. A safe topical treatment that addresses both would be a significant and potentially better therapeutic option for rosacea patients.
Maxwell Stock, CEO of Argyle Therapeutics, Inc., commented, "We are excited to be working in collaboration with Brickell's team of experienced drug developers and look forward to advancing SIG990 into the clinic. Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing effective drugs."
Andrew Sklawer, Vice President, Operations at Brickell Biotech, Inc. also stated: "SIG990 is a valuable addition to our pipeline, as it fits with our development strategy of focusing on novel therapeutics for the treatment of skin and ocular surface diseases. We are very excited about this partnership and are looking forward to progressing the development of SIG990 as a novel therapy for the treatment of rosacea."
About Argyle Therapeutics
Argyle was formed and founded in December 2010 and is a spin-out of Signum Biosciences. Argyle is a dermatology focused company developing novel cosmetic ingredients and drug compounds to address several skin conditions and major medical needs. Small molecules are developed from our proprietary Isoprenylcysteine (IPC) technology platform. Argyle also provides dermatology testing and custom assay development services.
About Brickell Biotech
BBI is a development-stage biopharmaceutical company focused on developing a R&D pipeline with innovative molecules that have potential to meet high unmet medical needs in the dermatology and ophthalmology fields. Working in collaboration with external research organizations, BBI will efficiently move forward with the development of these compounds through the various phases of clinical testing, regulatory filings and commercialization.
SOURCE Argyle Therapeutics, Inc.